AvalehtEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Viimane sulgemishind
0,69 $
Tänane vahemik
0,67 $ - 0,72 $
Aasta vahemik
0,66 $ - 3,13 $
Turuväärtus
15,16 mln USD
Keskmine maht
108,02 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 4,13 mln | −10,38% |
Põhitegevusega seonduv kulu | 4,85 mln | −10,01% |
Puhastulu | −2,07 mln | 38,42% |
Puhaskasumimarginaal | −50,18 | 31,30% |
Puhaskasum aktsia kohta | — | — |
EBITDA | −2,23 mln | 10,97% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 8,29 mln | −16,55% |
Kogu vara | 29,21 mln | −6,33% |
Kõik kohustused | 14,34 mln | −9,96% |
Kogu omakapital | 14,87 mln | — |
Emiteeritud aktsiate arv | 22,00 mln | — |
Hinna ja väärtuse suhe P/B | 1,02 | — |
Varade tasuvus | −23,48% | — |
Kapitali tasuvus | −33,02% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −2,07 mln | 38,42% |
Põhitegevuse rahakäive | −2,28 mln | 32,09% |
Investeeringute raha | −8,00 tuh | 52,94% |
Finantseerimise raha | 4,69 mln | — |
Raha ja raha ekvivalentide muutus | 2,41 mln | 171,42% |
Tasuta rahavoog | −1,11 mln | 57,80% |
Teave
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
Tegevjuht
Asutatud
2005
Veebisait
Töötajate arv
70